Immunotherapy: mechanism of action for<unk> , Pembrolizumab, Ipilimumab, Atezolizumab . Adapted from: First line Immunotherapy for Non-Small Cell Lung Cancer. Nasser NJ, Gorenberg M, Agbarya A. Pharmaceuticals 2020, 13(11), 373 https://doi.org/10.3390/ph13110373<unk>  (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).<unk>  is known as a checkpoint inhibitor drug.
Durvalumab
Evolocumab
Olaratumab
Ustekinumab
Emapalumab
Alirocumab
Tralokinumab
Dupilumab